SciSparc Subsidiary NeuroThera Labs Achieves Regulatory Milestone for Tourette Syndrome Clinical Trial

Article summary

SciSparc's subsidiary, NeuroThera Labs, has completed manufacturing and obtained batch release certification for its SCI-110 drug candidate, enabling the start of patient enrollment in a Phase IIb clinical trial.